Pharmacokinetics of oseltamivir in breast milk and maternal plasma

Laura G. Greer, Richard D. Leff, Vanessa Laibl Rogers, Scott W. Roberts, George H. McCracken, George D. Wendel, Jeanne S. Sheffield

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: Women in the postpartum period are at high risk for complications from influenza. Pharmacokinetic data of oseltamivir phosphate in postpartum women, however, are lacking. Study Design: Seven healthy patients within 48 hours of delivery were recruited. Each woman received 75 mg of oseltamivir phosphate. Plasma and breast milk samples were obtained at times 0, 0.5, 1, 2, 4, 8, 12, and 24 hours after the first dose. The samples were analyzed for oseltamivir and oseltamivir carboxylate levels. Using a noncompartmental model, area under the curve (AUC), maximum concentration (Cmax), time to maximum concentration, and half-life were estimated. Results: Oseltamivir phosphate and oseltamivir carboxylate were found in breast milk, although later and in lower levels than that found in plasma. The C max and AUC 0-24 was higher for the active metabolite than for the prodrug in both plasma and breast milk. Conclusion: Oseltamivir carboxylate was present in breast milk but in concentrations significantly lower than considered therapeutic in infants.

Original languageEnglish (US)
JournalAmerican Journal of Obstetrics and Gynecology
Volume204
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

Oseltamivir
Human Milk
Pharmacokinetics
Mothers
Phosphates
Postpartum Period
Area Under Curve
Prodrugs
Human Influenza
Half-Life
oseltamivir carboxylate

Keywords

  • breast milk pharmacokinetics
  • oseltamivir
  • oseltamivir excretion

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Pharmacokinetics of oseltamivir in breast milk and maternal plasma. / Greer, Laura G.; Leff, Richard D.; Rogers, Vanessa Laibl; Roberts, Scott W.; McCracken, George H.; Wendel, George D.; Sheffield, Jeanne S.

In: American Journal of Obstetrics and Gynecology, Vol. 204, No. 6, 06.2011.

Research output: Contribution to journalArticle

@article{360fb73fcc104ddd9f9fde77e922a8ed,
title = "Pharmacokinetics of oseltamivir in breast milk and maternal plasma",
abstract = "Objective: Women in the postpartum period are at high risk for complications from influenza. Pharmacokinetic data of oseltamivir phosphate in postpartum women, however, are lacking. Study Design: Seven healthy patients within 48 hours of delivery were recruited. Each woman received 75 mg of oseltamivir phosphate. Plasma and breast milk samples were obtained at times 0, 0.5, 1, 2, 4, 8, 12, and 24 hours after the first dose. The samples were analyzed for oseltamivir and oseltamivir carboxylate levels. Using a noncompartmental model, area under the curve (AUC), maximum concentration (Cmax), time to maximum concentration, and half-life were estimated. Results: Oseltamivir phosphate and oseltamivir carboxylate were found in breast milk, although later and in lower levels than that found in plasma. The C max and AUC 0-24 was higher for the active metabolite than for the prodrug in both plasma and breast milk. Conclusion: Oseltamivir carboxylate was present in breast milk but in concentrations significantly lower than considered therapeutic in infants.",
keywords = "breast milk pharmacokinetics, oseltamivir, oseltamivir excretion",
author = "Greer, {Laura G.} and Leff, {Richard D.} and Rogers, {Vanessa Laibl} and Roberts, {Scott W.} and McCracken, {George H.} and Wendel, {George D.} and Sheffield, {Jeanne S.}",
year = "2011",
month = "6",
doi = "10.1016/j.ajog.2011.01.056",
language = "English (US)",
volume = "204",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics of oseltamivir in breast milk and maternal plasma

AU - Greer, Laura G.

AU - Leff, Richard D.

AU - Rogers, Vanessa Laibl

AU - Roberts, Scott W.

AU - McCracken, George H.

AU - Wendel, George D.

AU - Sheffield, Jeanne S.

PY - 2011/6

Y1 - 2011/6

N2 - Objective: Women in the postpartum period are at high risk for complications from influenza. Pharmacokinetic data of oseltamivir phosphate in postpartum women, however, are lacking. Study Design: Seven healthy patients within 48 hours of delivery were recruited. Each woman received 75 mg of oseltamivir phosphate. Plasma and breast milk samples were obtained at times 0, 0.5, 1, 2, 4, 8, 12, and 24 hours after the first dose. The samples were analyzed for oseltamivir and oseltamivir carboxylate levels. Using a noncompartmental model, area under the curve (AUC), maximum concentration (Cmax), time to maximum concentration, and half-life were estimated. Results: Oseltamivir phosphate and oseltamivir carboxylate were found in breast milk, although later and in lower levels than that found in plasma. The C max and AUC 0-24 was higher for the active metabolite than for the prodrug in both plasma and breast milk. Conclusion: Oseltamivir carboxylate was present in breast milk but in concentrations significantly lower than considered therapeutic in infants.

AB - Objective: Women in the postpartum period are at high risk for complications from influenza. Pharmacokinetic data of oseltamivir phosphate in postpartum women, however, are lacking. Study Design: Seven healthy patients within 48 hours of delivery were recruited. Each woman received 75 mg of oseltamivir phosphate. Plasma and breast milk samples were obtained at times 0, 0.5, 1, 2, 4, 8, 12, and 24 hours after the first dose. The samples were analyzed for oseltamivir and oseltamivir carboxylate levels. Using a noncompartmental model, area under the curve (AUC), maximum concentration (Cmax), time to maximum concentration, and half-life were estimated. Results: Oseltamivir phosphate and oseltamivir carboxylate were found in breast milk, although later and in lower levels than that found in plasma. The C max and AUC 0-24 was higher for the active metabolite than for the prodrug in both plasma and breast milk. Conclusion: Oseltamivir carboxylate was present in breast milk but in concentrations significantly lower than considered therapeutic in infants.

KW - breast milk pharmacokinetics

KW - oseltamivir

KW - oseltamivir excretion

UR - http://www.scopus.com/inward/record.url?scp=79958117181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958117181&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2011.01.056

DO - 10.1016/j.ajog.2011.01.056

M3 - Article

VL - 204

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -